Is it Possible to Predict The Market Access of a New Pharmaceutical in Germany? A Systematic Evaluation of Federal Joint Committee Decisions on Early Benefit Assessments According to The German Law For Reforming The Market of Pharmaceuticals.
Value Health
; 17(7): A437, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-27201163
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article